There’s no reason to assume that every branded drug will fall victim to the “patent cliff.” Actions taken before drug patent expiration can extend drug life cycles.

Artificial intelligence is allowing chemists to find new way to synthesize drug molecules, and forcing drug developers to shore up their patent strategies.

The pharmaceutical industry’s practice of “evergreening” patents has become a contentious issue in healthcare policy debates. This controversial strategy involves

The Strategic Arbitrage of Innovation: A Definitive Legal, Commercial, and Regulatory Review of the 505(b)(2) Pathway Executive Summary In the

Branded generics are generic drugs that have been given proprietary brand names. They have a small, but profitable place in the U.S. pharmaceutical market.